Prelude Therapeutics Unveils Key Business Developments

Strategic Developments: Prelude Therapeutics has entered an exclusive option agreement with Incyte for its JAK2V617F mutant selective inhibitor program, which includes a $35 million upfront payment and potential future milestones, while also prioritizing the development of its KAT6A selective degrader program and pausing its SMARCA2 programs.

Financial Outlook: The company expects its cash runway to extend into 2027, potentially into the third quarter of 2028 if Incyte exercises its option on the JAK2 program, supported by approximately $52 million in cash and securities as of October 31, 2025.

Leadership Changes: Prelude announced the departure of President and Chief Medical Officer Jane Huang, with Victor Sandor stepping in to oversee clinical development for the KAT6A and JAK2 programs, bringing extensive oncology experience to the role.

Pipeline Focus: Prelude is advancing its KAT6A oral degrader program aimed at ER+ breast cancer and its JAK2V617F inhibitor program targeting myeloproliferative neoplasms, with plans to file an IND for KAT6A in mid-2026 and ongoing preclinical data supporting their innovative approaches.